What To Do When Last Pandemic’s Answer To The Next Pandemic Falters: Point Fingers
US congressional ‘coronavirus crisis’ panel explores Emergent BioSolutions COVID-19 vaccine launch failures while scoring points about private sector support.
You may also be interested in...
Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.
After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.